Vertex Historical Income Statement

VRTX Stock

USD 464.56 2.51 0.54%

Historical analysis of Vertex Pharmaceuticals income statement accounts such as Total Revenue of 10.4 B, Gross Profit of 9 B, Other Operating Expenses of 6.3 B or Operating Income of 4.5 B can show how well Vertex Pharmaceuticals performed in making a profits. Evaluating Vertex Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Vertex Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Vertex Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vertex Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

About Vertex Income Statement Analysis

Vertex Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Vertex Pharmaceuticals shareholders. The income statement also shows Vertex investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Vertex Pharmaceuticals Income Statement Chart

At this time, Vertex Pharmaceuticals' Cost Of Revenue is fairly stable compared to the past year. Income Before Tax is likely to rise to about 4.6 B in 2024, whereas Interest Expense is likely to drop slightly above 28.9 M in 2024.

Gross Profit Other Operating Expenses Total Operating Expenses Depreciation And Amortization

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Vertex Pharmaceuticals minus its cost of goods sold. It is profit before Vertex Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Vertex Pharmaceuticals. It is also known as Vertex Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Most accounts from Vertex Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Cost Of Revenue is fairly stable compared to the past year. Income Before Tax is likely to rise to about 4.6 B in 2024, whereas Interest Expense is likely to drop slightly above 28.9 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	6.7B	7.9B	8.6B	9.0B
Total Revenue	7.6B	8.9B	9.9B	10.4B

Gross Profit Total Revenue

Vertex Pharmaceuticals income statement Correlations

	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Depreciation And Amortization	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Research Development	Interest Expense	Selling General Administrative	Extraordinary Items	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Discontinued Operations	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Total Revenue		1.0	0.98	0.98	0.98	0.98	0.97	0.96	0.64	0.75	1.0	0.98	0.32	0.97	0.05	0.97	0.45	0.96	-0.04	0.14	0.65	0.62	0.66	0.79	0.94
Gross Profit	1.0		0.98	0.98	0.98	0.98	0.97	0.95	0.64	0.75	0.99	0.98	0.31	0.97	0.06	0.97	0.45	0.96	-0.04	0.14	0.64	0.62	0.65	0.79	0.94
Other Operating Expenses	0.98	0.98		0.93	0.93	0.94	1.0	0.91	0.59	0.78	0.98	0.93	0.3	0.99	0.11	0.99	0.55	0.93	-0.02	0.1	0.7	0.57	0.7	0.82	0.91
Operating Income	0.98	0.98	0.93		0.98	0.98	0.92	0.96	0.67	0.71	0.98	1.0	0.4	0.91	0.0	0.92	0.32	0.96	-0.15	0.17	0.62	0.64	0.64	0.77	0.94
Ebit	0.98	0.98	0.93	0.98		1.0	0.92	0.95	0.67	0.69	0.97	0.98	0.26	0.91	-0.06	0.92	0.34	0.95	0.02	0.16	0.63	0.65	0.65	0.77	0.93
Ebitda	0.98	0.98	0.94	0.98	1.0		0.92	0.95	0.67	0.71	0.97	0.98	0.27	0.91	-0.05	0.92	0.35	0.95	0.02	0.18	0.63	0.66	0.65	0.77	0.94
Total Operating Expenses	0.97	0.97	1.0	0.92	0.92	0.92		0.9	0.58	0.78	0.97	0.91	0.29	0.99	0.14	0.98	0.58	0.92	-0.01	0.08	0.7	0.56	0.7	0.82	0.9
Net Income	0.96	0.95	0.91	0.96	0.95	0.95	0.9		0.46	0.69	0.95	0.97	0.37	0.89	-0.06	0.91	0.33	0.99	-0.12	0.2	0.59	0.42	0.59	0.74	0.89
Income Tax Expense	0.64	0.64	0.59	0.67	0.67	0.67	0.58	0.46		0.51	0.62	0.67	0.28	0.57	0.14	0.56	0.16	0.46	-0.07	0.13	0.45	0.99	0.52	0.53	0.67
Depreciation And Amortization	0.75	0.75	0.78	0.71	0.69	0.71	0.78	0.69	0.51		0.77	0.72	0.44	0.78	0.23	0.79	0.47	0.71	-0.03	0.45	0.48	0.48	0.48	0.62	0.77
Cost Of Revenue	1.0	0.99	0.98	0.98	0.97	0.97	0.97	0.95	0.62	0.77		0.97	0.35	0.96	0.03	0.97	0.45	0.96	-0.07	0.14	0.67	0.6	0.68	0.81	0.94
Income Before Tax	0.98	0.98	0.93	1.0	0.98	0.98	0.91	0.97	0.67	0.72	0.97		0.42	0.9	-0.01	0.92	0.32	0.96	-0.15	0.21	0.62	0.64	0.63	0.77	0.94
Total Other Income Expense Net	0.32	0.31	0.3	0.4	0.26	0.27	0.29	0.37	0.28	0.44	0.35	0.42		0.28	0.21	0.31	-0.02	0.39	-0.89	0.46	0.24	0.16	0.23	0.29	0.36
Research Development	0.97	0.97	0.99	0.91	0.91	0.91	0.99	0.89	0.57	0.78	0.96	0.9	0.28		0.18	0.97	0.56	0.91	0.0	0.09	0.63	0.55	0.62	0.75	0.89
Interest Expense	0.05	0.06	0.11	0.0	-0.06	-0.05	0.14	-0.06	0.14	0.23	0.03	-0.01	0.21	0.18		0.13	0.46	0.0	-0.2	0.26	-0.14	0.1	-0.2	-0.15	0.06
Selling General Administrative	0.97	0.97	0.99	0.92	0.92	0.92	0.98	0.91	0.56	0.79	0.97	0.92	0.31	0.97	0.13		0.64	0.93	-0.02	0.16	0.68	0.54	0.68	0.81	0.88
Extraordinary Items	0.45	0.45	0.55	0.32	0.34	0.35	0.58	0.33	0.16	0.47	0.45	0.32	-0.02	0.56	0.46	0.64		0.42	0.17	0.11	0.3	0.16	0.31	0.36	0.33
Net Income From Continuing Ops	0.96	0.96	0.93	0.96	0.95	0.95	0.92	0.99	0.46	0.71	0.96	0.96	0.39	0.91	0.0	0.93	0.42		-0.13	0.22	0.59	0.42	0.58	0.73	0.89
Non Recurring	-0.04	-0.04	-0.02	-0.15	0.02	0.02	-0.01	-0.12	-0.07	-0.03	-0.07	-0.15	-0.89	0.0	-0.2	-0.02	0.17	-0.13		-0.15	-0.04	0.06	-0.04	-0.05	-0.06
Non Operating Income Net Other	0.14	0.14	0.1	0.17	0.16	0.18	0.08	0.2	0.13	0.45	0.14	0.21	0.46	0.09	0.26	0.16	0.11	0.22	-0.15		-0.16	0.11	-0.23	-0.11	0.18
Discontinued Operations	0.65	0.64	0.7	0.62	0.63	0.63	0.7	0.59	0.45	0.48	0.67	0.62	0.24	0.63	-0.14	0.68	0.3	0.59	-0.04	-0.16		0.44	0.93	0.93	0.7
Tax Provision	0.62	0.62	0.57	0.64	0.65	0.66	0.56	0.42	0.99	0.48	0.6	0.64	0.16	0.55	0.1	0.54	0.16	0.42	0.06	0.11	0.44		0.51	0.52	0.65
Interest Income	0.66	0.65	0.7	0.64	0.65	0.65	0.7	0.59	0.52	0.48	0.68	0.63	0.23	0.62	-0.2	0.68	0.31	0.58	-0.04	-0.23	0.93	0.51		0.98	0.63
Net Interest Income	0.79	0.79	0.82	0.77	0.77	0.77	0.82	0.74	0.53	0.62	0.81	0.77	0.29	0.75	-0.15	0.81	0.36	0.73	-0.05	-0.11	0.93	0.52	0.98		0.75
Reconciled Depreciation	0.94	0.94	0.91	0.94	0.93	0.94	0.9	0.89	0.67	0.77	0.94	0.94	0.36	0.89	0.06	0.88	0.33	0.89	-0.06	0.18	0.7	0.65	0.63	0.75

Click cells to compare fundamentals

Vertex Pharmaceuticals Account Relationship Matchups

Vertex Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Revenue	4.2B	6.2B	7.6B	8.9B	9.9B	10.4B
Gross Profit	3.6B	5.5B	6.7B	7.9B	8.6B	9.0B
Other Operating Expenses	3.0B	3.3B	4.8B	4.6B	6.0B	6.3B
Operating Income	1.2B	2.9B	2.8B	4.3B	4.3B	4.5B
Ebit	1.2B	3.2B	2.8B	4.3B	4.4B	4.6B
Ebitda	1.5B	3.3B	2.9B	4.4B	4.6B	4.8B
Total Operating Expenses	2.4B	2.6B	3.9B	3.5B	4.8B	5.0B
Net Income	1.2B	2.7B	2.3B	3.3B	3.6B	3.8B
Income Tax Expense	218.1M	405.2M	388.3M	910.4M	760.2M	798.2M
Depreciation And Amortization	260.3M	109.5M	125.6M	148.3M	181.3M	190.4M
Cost Of Revenue	547.8M	736.3M	904.2M	1.1B	1.3B	1.3B
Income Before Tax	1.4B	3.1B	2.7B	4.2B	4.4B	4.6B
Total Other Income Expense Net	197.4M	62.8M	(51.7M)	(75M)	72.3M	75.9M
Research Development	1.8B	1.8B	3.1B	2.5B	3.2B	3.3B
Interest Expense	58.5M	58.2M	61.5M	54.8M	44.1M	28.9M
Selling General Administrative	658.5M	770.5M	840.1M	887.2M	1.1B	1.2B
Net Income From Continuing Ops	1.2B	2.7B	2.3B	3.3B	3.6B	3.8B
Non Operating Income Net Other	255.9M	318.7M	9.8M	(20.2M)	(23.2M)	(22.1M)
Net Income Applicable To Common Shares	1.2B	2.7B	2.3B	3.3B	3.8B	4.0B
Tax Provision	218.1M	405.2M	388.3M	910.4M	760.2M	798.2M
Interest Income	63.7M	22.2M	4.9M	144.6M	614.7M	645.4M
Net Interest Income	5.2M	(35.9M)	(56.6M)	89.8M	570.6M	599.1M
Reconciled Depreciation	106.9M	109.5M	125.6M	148.3M	181.3M	126.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vertex Historical Income Statement

About Vertex Income Statement Analysis

Vertex Pharmaceuticals Income Statement Chart

Gross Profit

Other Operating Expenses

Total Operating Expenses

Depreciation And Amortization

Vertex Pharmaceuticals income statement Correlations

Vertex Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vertex Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for Vertex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Cost Of Revenue	+ 0.99	Gross Profit

Non Recurring	- 0.89	Total Other Income Expense Net
Interest Income	- 0.23	Non Operating Income Net Other
Interest Income	- 0.2	Interest Expense
Non Recurring	- 0.2	Interest Expense
Discontinued Operations	- 0.16	Non Operating Income Net Other
Non Operating Income Net Other	- 0.15	Non Recurring